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Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH), which has been recognised in the
past in no more than 0.1% patients who had undergone acute pulmonary embolism (APE), is
currently being found in as many as 3–8% of these patients.
The pathophysiology of CTEPH is not fully understood, although the relationship with venous
thromboembolism has a firm basis. The potential causes of the disease include symptomatic
but unrecognised episodes of APE, repetitive episodes of silent pulmonary microemboli and
recurrence of symptomatic APE in the course of initial treatment during and after the cessa-
tion of secondary antithrombotic prophylaxis. The pathomechanisms postulated are failure to
lyse the initial emboli, coagulopathy, thrombosis in situ and peripheral propagation of the
residual emboli. The role of arteriopathy in the initial stage of CTEPH is controversial.
CTEPH should be expected in all patients with chronic exertional dyspnoea and exercise
intolerance in whom other causes can be excluded. The role of medical history, physical
examination, electrocardiography and echocardiography in recognition is under discussion.
Early diagnosis, before the development of pulmonary hypertension, is likely to ensure a good
prognosis in continuously anticoagulated patients. Most patients, however, are diagnosed late
and pulmonary hypertension is already marked. At this stage of CTEPH pulmonary endarter-
ectomy is the treatment of choice for suitable patients with proximal emboli. Diagnosis of
CTEPH at the stage of decompensated cor pulmonale considerably worsens the prognosis in
solely anticoagulated patients and decreases the benefits of pulmonary endarterectomy. (Folia
Cardiol. 2006; 13: 338–342)
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Chronic thromboembolic pulmonary hyperten-
sion (CTEPH) is now more generally recognised as
a component of chronic venous thromboembolism
than previously. The pathophysiology is still deba-
table and the diagnosis seems to be even more dif-
ficult than that of acute pulmonary embolism (APE).
At the end of the 20th century it was estimated that
CTEPH develops in 0.1–0.5% of patients who have
experienced an incident of APE. This means that
there are at least 1800 new cases of CTEPH a year
in Poland. Recent observations indicate, however,
that a higher rate of incidence can be expected.
Pengo et al. [3] found that CTEPH developed in
3.8% of patients with APE within a two-year follow-
up period. In a study by Remy-Jardin et al. [4]
CTEPH was found in as many as 8% of 62 patients
after an episode of massive APE. The real inciden-
ce of CTEPH may be even greater because it is
believed that most of the thromboembolic events
which initiate CTEPH are not recognised because
they are subsymptomatic or even asymptomatic [5, 6].
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The natural history of CTEPH can start with
symptomatic but unrecognised and thus untreated
APE events. The symptoms of APE are highly
unspecified, both those which occur frequently,
such as dyspnoea, chest pain, tachycardia and ta-
chypnoea, and those which occur relatively rarely,
such as epistaxis and syncope. The results of ana-
tomopathological studies show that when pulmona-
ry embolism was found to be the cause of death,
either alone or as a concomitant disease, antemor-
tem recognition only reached 30% [7, 8]. When APE
diagnosis is based solely on clinical symptoms, the
percentage of false positive recognition reaches
70% [9]. It seems that the problem of unsatisfactory
diagnosis of APE, even when it is fully symptomatic,
cannot be solved by the use of advanced diagnostic
techniques alone. The continuous awareness that
APE occurs relatively often and can be masked by
other mostly cardiac diseases is a reason for orde-
ring proper diagnostic tests. Pulmonary embolism
should therefore be suspected among patients with
atrial fibrillation, chronic cardiac failure, and coro-
nary artery disease. We reported a series of six
pulmonary embolism cases in which false diagno-
sis of myocardial infarction and chronic coronary
ischaemic disease was based on symptoms of chest
pain and misinterpretation of electrocardiograms.
As a consequence, patients were treated continu-
ously with aspirin instead of anticoagulants and this
was probably the reason for the development of
CTEPH in five of them [10]. Acute chest pain ac-
companied by electrocardiographic signs of ischa-
emic injury and/or troponin elevation represent
a basis for diagnosing acute coronary syndrome
(ACS), although these symptoms may also be fo-
und in APE. Of 625 consecutive patients who were
admitted to the local catheterisation laboratory for
early invasive treatment of ACS, APE was recogni-
sed in 7 out of 18 patients in whom coronary angio-
graphy had been normal or near normal [11].
It is assumed that some CTEPH cases can de-
velop as a result of recurrent asymptomatic pulmo-
nary microemboli. The frequent occurrence of si-
lent pulmonary embolism in patients with deep ve-
nous thrombosis (DVT) was already being reported
in the 1980s, although the results were based on
a small patient population [12, 13]. These results
were confirmed later by the results of a larger mul-
ti-centre study involving 622 patients with proxi-
mal DVT. In this study silent pulmonary embolism
was found in nearly half the patients [14]. In the-
ory, the proper anticoagulation of DVT patients who
have concomitant silent pulmonary embolism
should prevent persistence of thrombi which could
create the substratum for CTEPH development.
However, Nielsen et al. who followed scintigraphi-
cally 87 patients with symptomatic DVT, 49% of
whom had silent pulmonary embolism, could find
no resolution of the emboli in 70% of cases after
60 days of observation independent of anti-throm-
botic intervention [15]. It can be speculated that chro-
nic pulmonary emboli could be the consequence of
previous, possibly multiple, unrecognised untreated
and thus unresolved thromboembolic episodes.
Obviously, silent pulmonary emboli can be expected
even more frequently in patients with asymptoma-
tic DVT. In one anatomopathological study, antemor-
tem silent DVT was found in a majority of autopsies
[16]. In a study by Girard et al. [17] 82% of patients
with APE had concomittant DVT, which in 75% pa-
tients was asymptomatic.
CTEPH can develop as a final outcome of em-
bolic recurrence in the course of symptomatic and
recognised episodes of APE. These may be expec-
ted mostly during the first two weeks after the in-
itial episode and can be considerably limited by ap-
propriate therapy [18, 19] The recurrence can also
occur during proper secondary thromboembolic
prophylaxis and their number sharply increases, up
to 4–5%, after anticoagulation has been stopped.
Subsequently, the level of recurrence decreases to
reach a steady 0.5% in the 9th month [20]. This ra-
ises the problem of termination of the anticoagula-
tion and in this context the individual risk of recur-
rence and bleeding should be taken into account.
The mode of anticoagulation during secondary
thromboembolic prophylaxis also exerts a signifi-
cant impact on embolic recurrence. In a study com-
paring the results of conventional anticoagulation
(INR 2–3) with subtherapeutic (INR 1.5–2) it was
shown that the risk of recurrence was diminished
by 90% and 64% respectively without significant
differences in the bleeding [21]. The impact of re-
currence on CTEPH development, however, has
not been established. In common with others, we
have found that, at least in anticoagulated APE pa-
tients, recurrence did not increase pulmonary hy-
pertension [22–24]. Instead CTEPH may develop
after episodes of recurrent pulmonary embolism in
non-anticoagulated patients [1, 25].
CTEPH can also develop in patients with APE
and with pulmonary hypertension at the time of
diagnosis. In some pulmonary hypertension does
not return to normal despite adequate therapy and
the choice of therapy administered during APE does
not seem to influence the outcome. The results of
randomised trials have shown that thrombolysis
resolves pulmonary emboli more rapidly that
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anticoagulation during the first 24 hours, although
this effect has been lost by the 7th day of therapy [26].
These results were confirmed by observations
made over the course of a year which were unable
to show that fibrolysis administered during the acute
stage of pulmonary embolism was any more success-
ful at preventing patients from developing CTEPH
than anticoagulation [22, 24]. Indeed, this depends
largely on baseline pulmonary artery pressure. Pul-
monary hypertension is found in approximately 70–
–80% of patients with APE, despite the fact that
mean pulmonary artery pressure hardly ever exceeds
40 mm Hg, even in patients with massive APE [27].
It can reach much higher values in patients with
concomitant cardiopulmonary disease or if it results
from previously unrecognised, recurrent pulmonary
embolism episodes [28]. Ribeiro et al. [22], who per-
formed serial echocardiographic studies during
a one-year follow up of patients after an APE epi-
sode, found that pulmonary hypertension decreased
only during the first 6 weeks of routine treatment
and that patients with a baseline pulmonary artery
pressure > 50 mm Hg have the potential to develop
CTEPH. The results of our own study indicate,
however, that during anticoagulation extended to
one year pulmonary hypertension decreases or
even returns to normal after the six-week period
in some patients. This may suggest that prolonged
secondary thromboembolic prophylaxis after an epi-
sode of APE can be more effective in preventing
patients with APE from developing CTEPH [24].
Therefore despite the mysterious nature of
CTEPH as emphasised by numerous investigators,
behind many cases lie unrecognised symptomatic
or inappropriately treated APE episodes and insuf-
ficient secondary antithrombotic prophylaxis. This
implies that CTEPH can, potentially, be more effi-
ciently prevented in future, provided that APE dia-
gnosis and therapy are improved. It would also be
helpful to determine why CTEPH is activated only
in some patients after APE. Even if the connection
between CTEPH and venous thromboembolism has
reliable a basis, its aetiopathogenesis has not been
fully established. It is not known whether “residu-
al” emboli after an APE episode and silent pulmo-
nary embolism accompanied DVT can activate
CTEPH; their nature remains barely understood.
It is possible to speculate that they represent the
“exhaustion” of endogenous fibrinolysis following
the repeated occurrence of emboli, yet fibrinolysis
defects are rarely found [29]. The results of studies
on coagulation are not uniform and in one recent
report a significantly higher concentration of anti-
phospholipid antibodies was found in CTEPH than
in patients with idiopathic pulmonary arterial hyper-
tension. As a result, silent thrombotic changes co-
uld propagate distally and initiate CTEPH [30]. The
significance of “in situ thrombosis”, however, is not
obvious. There is also a hypothesis that both in
CTEPH and in idiopathic pulmonary arterial hyper-
tension the primary lesions are arteriopathic in na-
ture and that thrombosis is merely a secondary pro-
cess [31].
The diagnosis of an early stage of CTEPH in
patients without an obvious history of APE is extre-
mely difficult. The symptoms may be slight or pa-
tients may be   asymptomatic, although pulmonary
pressure is constantly increasing. At first it is con-
tained within the normal range at rest. However, it
can rise during effort. Measurement of pulmonary
pressure during an exercise test may well be help-
ful in recognising the early stages of the disease.
In the natural history of CTEPH this period is ter-
med the “honeymoon period”, which usually pas-
ses into the symptomatic period with increased fa-
tigue and dyspnoea on exertion. These symptoms
are, however, highly non-specific. Thus the incre-
ased awareness of the relatively high incidence of
CTEPH should lead to the disease being taken into
account, especially in patients in which the reason
for chronic dyspnoea on exertion is not clear. We
found CTEPH in as many as 28 out of 90 (31%) con-
secutive patients who were admitted with this
symptom, although the high percentage of CTEPH
patients was obviously specific to our specialised
department [32]. Early diagnosis of CTEPH may be
of vital value. It is believed that patients with mild
and moderate pulmonary hypertension can benefit
from proper anticoagulation alone. In our own ma-
terial of newly diagnosed CTEPH patients who had
not yet been operated on, all those with pulmonary
arterial systolic pressure < 55 mm Hg survived the
three-year study. Pulmonary hypertension decre-
ased and exercise tolerance improved [33].
At a more advanced stage of CTEPH with high
pulmonary hypertension and right ventricular over-
load decreased exercise tolerance may be accom-
panied by ischaemic chest pain and syncope. Only
then may an enhanced and split-second sound be
heard over the pulmonary artery valve and the sy-
stolic murmur of tricuspid valve regurgitation. Ty-
pical for CTEPH, but very rare, is the continuous
or systolic murmur over lung fields described by
Augers and Moser, which is a consequence of par-
tial obstruction of the major pulmonary arteries or
recanalisation of thrombi [34]. A chest X-ray is usu-
ally normal or can reveal other causes of chronic
dyspnoea. A routine electrocardiogram can show
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signs of right ventricular overload, especially in the
case of high pulmonary pressure. In a population of
56 patients who had experienced APE in the past
the highest incidences of negative T wave in the
precordial V1–V5 leads, negative T waves in II, III
and aVF, pulmonary P wave and right axis devia-
tion > 90% were determined as 43%, 32%, 30% and
30% respectively. These ECG signs of right ven-
tricular overload were of positive value in predic-
ting CTEPH, which ranged from 80 to 100% [35].
Signs of right ventricular overload could be much
better recognised and assessed by transthoracic
echocardiography, whereas transoesophageal echo-
cardiography can visualise proximal emboli. Conti-
nuous valve Doppler measurement of the peak ve-
locity of the regurgitant jet across the tricuspid
valve is the basis for the non-invasive assessment
of systolic pulmonary artery pressure. This pres-
sure correlates well with the pressure directly
measured during pulmonary haemodynamics, altho-
ugh sometimes it can be underestimated [36, 37].
Pulmonary scintigraphy shows perfusion defects,
although the greatest value of this study is to exc-
lude CTEPH in patients with pulmonary hyperten-
sion when the result is negative [38]. Introducing
modern multi-detector row spiral computed tomo-
graphy increased considerably the possibility of
recognising and assessing pulmonary emboli and
the appearance of pulmonary vasculature, lung flow
and lung parenchyma. Nevertheless, pulmonary
angiography accompanied by pulmonary haemody-
namics best confirms the diagnosis and establishes
the surgical feasibility of CTEPH. It must, howe-
ver, be remembered, that the appearance of an an-
giogram in CTEPH is different from that in APE. It
is more complicated, reflecting chronic processes
of recanalisation and organisation. Thus, apart from
“cut-off” changes, webs, bands, and irregularly nar-
rowed vessels can be seen [39].
CTEPH is frequently recognised as late as
during the phase of overt right ventricular failure,
when episodes of peripheral oedemas, hepatome-
galy, ascites and jugular vein distension join the
chronic dyspnoea and exercise intolerance. The
survival of these patients is short, a few years at
most, similar to survival in decompensated hipoxic
cor pulmonale [40]. The prognosis at this stage can
not be improved significantly by anticoagulation.
The reason for this seems to be an irreversible re-
modelling of the pulmonary vessels which is not
susceptible to anticoagulation, while thrombosis
may play a less important role. Even in this advan-
ced phase of CTEPH, patients with proximal em-
boli can be successfully operated on. However, their
perioperative prognosis and haemodynamic impro-
vement are worse then those operated on during
an earlier phase of CTEPH [41].
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